scholarly journals Clinical Results of Fibroblast Activation Protein (FAP) Specific PET and Implications for Radiotherapy Planning: Systematic Review

Cancers ◽  
2020 ◽  
Vol 12 (9) ◽  
pp. 2629
Author(s):  
Paul Windisch ◽  
Daniel R. Zwahlen ◽  
Stefan A. Koerber ◽  
Frederik L. Giesel ◽  
Jürgen Debus ◽  
...  
Keyword(s):  
Systematic Review ◽  
Small Molecules ◽  
Imaging Modality ◽  
Clinical Results ◽  
Fibroblast Activation Protein ◽  
Emission Tomography ◽  
Radiotherapy Planning ◽  
Limited Data ◽  
Fibroblast Activation ◽  
Positron Emission

Small molecules targeting fibroblast activation protein (FAP) have emerged as a new group of tracers for positron emission tomography (PET) in 2018. The purpose of this systematic review is therefore to summarize the evidence that has been gathered to date in patients and to discuss its possible implications for radiotherapy planning. The MEDLINE database was searched for the use of FAP-specific PET in cancer patients and the records were screened according to PRISMA guidelines. Nineteen studies were included. While dedicated analyses of FAP-specific PET for radiotherapy planning were available for glioblastoma, head and neck cancers, lung cancer, and tumors of the lower gastrointestinal tract, there is still very limited data for several epidemiologically significant cancers. In conclusion, FAP-specific PET represents a promising imaging modality for radiotherapy planning that warrants further research.

scholarly journals Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: systematic review

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Paul Windisch ◽  
Daniel R. Zwahlen ◽  
Frederik L. Giesel ◽  
Eberhard Scholz ◽  
Patrick Lugenbiel ◽  
...  
Keyword(s):  
Systematic Review ◽  
Prospective Studies ◽  
Case Reports ◽  
Clinical Results ◽  
Fibroblast Activation Protein ◽  
The Body ◽  
Benign Tumors ◽  
Fibroblast Activation ◽  
Related Disease ◽  
Positron Emission

Abstract Purpose Small molecules targeting fibroblast activation protein (FAP) have emerged as a new group of tracers for positron emission tomography (PET) in 2018. While most of the existing literature has been focussed on the application of FAP-specific PET in various kinds of cancers, some researchers have, both intentionally or unintentionally, used FAP-specific PET in patients with non-cancerous diseases. The purpose of this systematic review is therefore to summarize the available evidence of FAP-specific PET for non-malignant indications. Methods The MEDLINE database was searched for studies presenting the clinical use of FAP-specific PET, the records were screened according to PRISMA guidelines and articles containing patients suffering from non-malignant diseases were included. Results Sixteen studies with 303 patients were included. FAP-specific PET has been used in cardiac imaging, IgG4-related disease, benign tumors as well as various kinds of inflammation. Two prospective studies on FAP-specific PET for IgG4-related disease show its potential to differentiate inflammatory from fibrotic lesions, which could be used to determine the management of these patients. Conclusion While publications on FAP-specific PET for non-malignant indications are mostly limited to case reports and incidental findings, the first retrospective and prospective studies present promising results for IgG4-related as well as cardiovascular disease that warrant further research. Several currently recruiting trials will add to the body evidence in the next few years.

scholarly journals Head-to-Head Comparison of Fibroblast Activation Protein Inhibitors (FAPI) Radiotracers versus [18F]F-FDG in Oncology: A Systematic Review

2021 ◽  
Vol 22 (20) ◽  
pp. 11192
Author(s):  
Giorgio Treglia ◽  
Barbara Muoio ◽  
Hessamoddin Roustaei ◽  
Zahra Kiamanesh ◽  
Kamran Aryana ◽  
...  
Keyword(s):  
Systematic Review ◽  
Fdg Pet ◽  
Liver Tumors ◽  
Fibroblast Activation Protein ◽  
Cochrane Library ◽  
Protein Inhibitors ◽  
Primary Tumors ◽  
Fibroblast Activation ◽  
Positron Emission ◽  
Pet Radiotracers

Several recent studies comparing radiolabeled fibroblast activation protein inhibitors (FAPI) and fluorine-18 fluorodeoxyglucose ([18F]F-FDG) as positron emission tomography (PET) radiotracers in oncology have been published. The aim of this systematic review is to perform an updated evidence-based summary about the comparison of these PET radiotracers in oncology to better address further research in this setting. Studies or subsets of studies comparing radiolabeled FAPI and [18F]F-FDG as PET radiotracers in oncology were eligible for inclusion in this systematic review. A systematic literature search of PubMed/MEDLINE and Cochrane library databases was performed until August 2021. Literature data about the comparison of [18F]F-FDG and radiolabeled FAPI are rapidly increasing. Overall, taking into account radiotracer uptake and tumor-to-background uptake ratio, compared to [18F]F-FDG PET, an equal or higher detection of primary tumors and/or metastatic lesions was usually demonstrated by using radiolabeled FAPI PET. In particular, the cancer entities with better detection rate of tumor lesions by using radiolabeled FAPI PET, compared to [18F]F-FDG PET, were gastrointestinal tumors, liver tumors, breast cancer and nasopharyngeal carcinoma. Further comparison studies are needed to better evaluate the best field of application of radiolabeled FAPI PET.

scholarly journals Advanced Imaging Techniques for Radiotherapy Planning of Gliomas

Cancers ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 1063
Author(s):  
Antonella Castellano ◽  
Michele Bailo ◽  
Francesco Cicone ◽  
Luciano Carideo ◽  
Natale Quartuccio ◽  
...  
Keyword(s):  
Radiation Treatment ◽  
Imaging Modality ◽  
Imaging Techniques ◽  
Clinical Results ◽  
Target Volume ◽  
Radiotherapy Planning ◽  
Tumor Control ◽  
Current Standard ◽  
Volume Delineation ◽  
Hemodynamic Information

The accuracy of target delineation in radiation treatment (RT) planning of cerebral gliomas is crucial to achieve high tumor control, while minimizing treatment-related toxicity. Conventional magnetic resonance imaging (MRI), including contrast-enhanced T1-weighted and fluid-attenuated inversion recovery (FLAIR) sequences, represents the current standard imaging modality for target volume delineation of gliomas. However, conventional sequences have limited capability to discriminate treatment-related changes from viable tumors, owing to the low specificity of increased blood-brain barrier permeability and peritumoral edema. Advanced physiology-based MRI techniques, such as MR spectroscopy, diffusion MRI and perfusion MRI, have been developed for the biological characterization of gliomas and may circumvent these limitations, providing additional metabolic, structural, and hemodynamic information for treatment planning and monitoring. Radionuclide imaging techniques, such as positron emission tomography (PET) with amino acid radiopharmaceuticals, are also increasingly used in the workup of primary brain tumors, and their integration in RT planning is being evaluated in specialized centers. This review focuses on the basic principles and clinical results of advanced MRI and PET imaging techniques that have promise as a complement to RT planning of gliomas.

scholarly journals Value of PET imaging for radiation therapy

2021 ◽  
Author(s):  
Constantin Lapa ◽  
Ursula Nestle ◽  
Nathalie L. Albert ◽  
Christian Baues ◽  
Ambros Beer ◽  
...  
Keyword(s):  
Radiation Treatment ◽  
Imaging Modality ◽  
Tumour Response ◽  
Emission Tomography ◽  
Current Status ◽  
Response Monitoring ◽  
Radiation Treatment Planning ◽  
Policy Makers ◽  
Comprehensive Review ◽  
Positron Emission

AbstractThis comprehensive review written by experts in their field gives an overview on the current status of incorporating positron emission tomography (PET) into radiation treatment planning. Moreover, it highlights ongoing studies for treatment individualisation and per-treatment tumour response monitoring for various primary tumours. Novel tracers and image analysis methods are discussed. The authors believe this contribution to be of crucial value for experts in the field as well as for policy makers deciding on the reimbursement of this powerful imaging modality.

Sign in / Sign up

Export Citation Format

Share Document